Related content

Pharmacogenomic data submissions to the FDA: clinical case studies

By Trepicchio William L   Williams Grant A   Essayan David   Hall Sue T   Harty Lea C   Shaw Peter M   Spear Brian B   Wang Sue Jane   Watson Mark L  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

By Ruañño Gualberto   Collins Jerry M   Dorner Andrew J   Wang Sue-Jane   Guerciolini Roberto   Huang Shiew-Mei  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 513-517

Future Medicine

Access to resources Recommend Favorite

Joint pharmacogenomic data submissions guidance released by the US FDA, European Commission and the European Medicines Agency

By  

Pharmacogenomics, Vol. 7, Iss. 5, 2006-07 ,pp. : 659-661

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data: FDA voluntary and required submission guidance

By Salerno Ronald A   Lesko Lawrence J  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 503-505

Future Medicine

Access to resources Recommend Favorite

Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies

By Burczynski Michael E   Dorner Andrew J  

Pharmacogenomics, Vol. 7, Iss. 2, 2006-03 ,pp. : 187-202

Future Medicine

Access to resources Recommend Favorite